<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596022</url>
  </required_header>
  <id_info>
    <org_study_id>6716</org_study_id>
    <nct_id>NCT02596022</nct_id>
  </id_info>
  <brief_title>The Effect of Glutamatergic Modulation on Cocaine Self-administration</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Repeated drug consumption may progress to problematic use by triggering neuroplastic
      adaptations that attenuate sensitivity to natural rewards while increasing reactivity to
      craving and drug cues. Converging evidence suggests that glutamate modulation may work to
      correct these adaptations and rapidly restore motivation for delayed non-drug rewards
      relative to immediate drug use. Using an established laboratory model aimed at evaluating
      behavioral shifts in the salience of cocaine now vs. money later, the investigators will test
      the effect of CI-581a on cocaine self-administration as compared to the active control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Choices to Self-administer Cocaine (Out of 5 Choices)</measure>
    <time_frame>24 hours post-infusion</time_frame>
    <description>Participants provided 5 choices (cocaine 25 mg now vs. $11 later), with choices spaces 15 minutes apart over the course of the session.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>CI-581a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of CI-581a followed 2 weeks later by CI-581b</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CI-581b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of CI-581b followed 2 weeks later by CI-581a</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CI-581a</intervention_name>
    <description>a 50 minute infusion 24 hours prior to cocaine self-administration session</description>
    <arm_group_label>CI-581a</arm_group_label>
    <arm_group_label>CI-581b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CI-581b</intervention_name>
    <description>a 50 minute infusion 24 hours prior to cocaine self-administration session</description>
    <arm_group_label>CI-581a</arm_group_label>
    <arm_group_label>CI-581b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Active cocaine dependence with at least 8 days of use or at least 4 binges of large
             amounts (&gt;$200/occasion) over the past 30 days, and displaying at least one positive
             utox during screening

          2. Physically healthy

          3. No adverse reactions to study medications

          4. 21-55 years of age

          5. Capacity to consent and comply with study procedures, including sufficient proficiency
             in English

          6. Not seeking treatment

        Exclusion Criteria:

          1. Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia,
             any psychotic illness, including substance induced psychosis, and current
             substance-induced mood disorder with HAMD score &gt; 12.

          2. Physiological dependence on another substance, such as alcohol, opioids, or
             benzodiazepines, excluding caffeine, nicotine, and cannabis

          3. Delirium, Dementia, Amnesia, Cognitive Disorders, or Dissociative disorders

          4. Current suicide risk or a history of suicide attempt within the past year

          5. Pregnant or interested in becoming pregnant during the study period

          6. Any of the following cardiac conditions: clinically significant left ventricular
             hypertrophy, angina, clinically significant arrhythmia, or mitral valve prolapse

          7. Unstable physical disorders which might make participation hazardous such as end-stage
             AIDS, hypertension (&gt;140/90), WBC &lt; 3.5, active hepatitis or other liver disease with
             elevated transaminase levels (&lt; 2-3 X upper limit of normal will be considered
             acceptable if PT/PTT is normal), renal failure (creat &gt; 2, BUN &gt;40), or untreated
             diabetes

          8. Previous history of ketamine or midazolam misuse or abuse, and a history of an adverse
             reaction/experience with prior exposure to cocaine, ketamine or midazolam

          9. Recent history of significant violence (past 2 years)

         10. Abnormal pseudocholinesterase level

         11. First degree relative with a psychotic disorder (bipolar disorder, schizophrenia,
             schizoaffective disorder, or psychosis NOS)

         12. BMI &gt; 35, or a history of documented obstructive sleep apnea

         13. On psychotropic or other medications whose effect could be disrupted by participation
             in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Dakwar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia College of Physicians and Surgeons</affiliation>
  </overall_official>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <results_first_submitted>August 7, 2017</results_first_submitted>
  <results_first_submitted_qc>September 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 17, 2017</results_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CI-581a First, Followed by CI-581b</title>
          <description>Administration of CI-581a followed 2 weeks later by CI-581b
CI-581a: a 50 minute infusion 24 hours prior to cocaine self-administration session
CI-581b: a 50 minute infusion 24 hours prior to cocaine self-administration session</description>
        </group>
        <group group_id="P2">
          <title>CI-581b First, Followed by CI-581a</title>
          <description>Administration of CI-581b followed 2 weeks later by CI-581a
CI-581a: a 50 minute infusion 24 hours prior to cocaine self-administration session
CI-581b: a 50 minute infusion 24 hours prior to cocaine self-administration session</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CI-581a First, Followed by CI-581b</title>
          <description>Administration of CI-581a followed 2 weeks later by CI-581b
CI-581a: a 50 minute infusion 24 hours prior to cocaine self-administration session
CI-581b: a 50 minute infusion 24 hours prior to cocaine self-administration session</description>
        </group>
        <group group_id="B2">
          <title>CI-581b First, Followed by CI-581a</title>
          <description>Administration of CI-581b followed 2 weeks later by CI-581a
CI-581a: a 50 minute infusion 24 hours prior to cocaine self-administration session
CI-581b: a 50 minute infusion 24 hours prior to cocaine self-administration session</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.6" spread="6.1"/>
                    <measurement group_id="B2" value="48.6" spread="6.1"/>
                    <measurement group_id="B3" value="48.6" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Choices to Self-administer Cocaine (Out of 5 Choices)</title>
        <description>Participants provided 5 choices (cocaine 25 mg now vs. $11 later), with choices spaces 15 minutes apart over the course of the session.</description>
        <time_frame>24 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CI-581a</title>
            <description>CI-581a: a 50 minute infusion 24 hours prior to cocaine self-administration session</description>
          </group>
          <group group_id="O2">
            <title>CI-581b</title>
            <description>CI-581a: a 50 minute infusion 24 hours prior to cocaine self-administration session</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Choices to Self-administer Cocaine (Out of 5 Choices)</title>
          <description>Participants provided 5 choices (cocaine 25 mg now vs. $11 later), with choices spaces 15 minutes apart over the course of the session.</description>
          <units>number of cocaine choices</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="1.3"/>
                    <measurement group_id="O2" value="4.33" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CI-581a First, Followed by CI-581b</title>
          <description>Administration of CI-581a followed 2 weeks later by CI-581b
CI-581a: a 50 minute infusion 24 hours prior to cocaine self-administration session
CI-581b: a 50 minute infusion 24 hours prior to cocaine self-administration session</description>
        </group>
        <group group_id="E2">
          <title>CI-581b First, Followed by CI-581a</title>
          <description>Administration of CI-581b followed 2 weeks later by CI-581a
CI-581a: a 50 minute infusion 24 hours prior to cocaine self-administration session
CI-581b: a 50 minute infusion 24 hours prior to cocaine self-administration session</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Sherman</name_or_title>
      <organization>NYSPI</organization>
      <phone>6467747158</phone>
      <email>lsherma@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

